Novavax (NASDAQ:NVAX) & DNAPrint Genomics (OTCMKTS:DNAG) Critical Comparison

Novavax (NASDAQ:NVAX) and DNAPrint Genomics (OTCMKTS:DNAG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Novavax and DNAPrint Genomics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4	1	5	0	2.10
DNAPrint Genomics	0	0	0	0	0.00

Novavax presently has a consensus price target of $12.13, suggesting a potential upside of 18.99%. Given Novavax’s stronger consensus rating and higher possible upside, research analysts plainly believe Novavax is more favorable than DNAPrint Genomics.

Earnings & Valuation

This table compares Novavax and DNAPrint Genomics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12 billion	1.49	$440.30 million	($0.58)	-17.57
DNAPrint Genomics	N/A	N/A	N/A	N/A	N/A

Novavax has higher revenue and earnings than DNAPrint Genomics.

Profitability

This table compares Novavax and DNAPrint Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
DNAPrint Genomics	N/A	N/A	N/A

Institutional & Insider Ownership

53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Novavax beats DNAPrint Genomics on 7 of the 9 factors compared between the two stocks.

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

About DNAPrint Genomics

DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. It offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer’s proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents. The company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany.